Abbott’s COMPARE trial demonstrates that Xience V Everolimus Eluting Coronary Stent System has shown better outcomes in safety and efficacy measures compared to the Taxus Liberte Paclitaxel-Eluting Coronary
ThromboGenics has completed the enrollment of the US phase III trial evaluating microplasmin for the non-surgical treatment of eye disease. The trial TG-MV-006 has completed enrollment of 326
A phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and effective in preventing HIV
Richter-Helm BioLogics has completed the modernisation of it´s GMP-production facility in Hannover. Richter-Helm produces recombinant proteins, plasmid DNA and vaccines for biopharmaceuticals. The company said that the production
China Biologic Products (China Biologic) entered into a research and development agreement with the Institute of Blood Transfusion (IBT) on September 11, 2009, to strengthen the company’s research
Eisai has announced that it has reached an agreement with Pfizer regarding the strategic alliance for the Alzheimer’s Disease treatment, Aricept (donepezil hydrochloride). Reportedly Eisai and Pfizer have
Osmetech has made the strategic decision to build its own direct sales force in the US with the objective of targeting key molecular diagnostic testing laboratories as well
Sandoz has completed acquisition of EBEWE Pharma’s specialty generic injectables business for $1.3 billion. The transaction offers Sandoz a complementary portfolio of differentiated generics, with more than 15
Arch Chemicals has appointed three new members to its senior management team. The individuals are assuming the operational responsibilities that had previously been managed by the company’s former
Cephalon has announced that the FDA has granted a priority review for its supplemental New Drug Application (sNDA) for NUVIGIL (armodafinil) tablets [C-IV], which was filed in June
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.